Loading
NYSEHealthcareDrug Manufacturers - General
Latest quote
$275.23
−$3.20 · -1.15%
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
Previous close
$275.23
−$3.20 · -1.15%
Regular session · ET · Market data may be delayed.
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
Day range
Current $275.23
52-week range
Current $275.23
Regular session · ET · Market data may be delayed.
AI-powered factor overview
GoAI Score
Buy
Favorable setup — positive multi-factor alignment
Valuation
69
Undervalued
Sentiment
70
Bullish
Risk
16
Low Risk
Momentum
61
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
Day range
Current $275.23
52-week range
Current $275.23
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 94.19B USD | 88.82B USD | 85.16B USD | 79.99B USD | 78.74B USD |
| Cost of goods sold | 25.64B USD | 27.47B USD | 26.55B USD | 24.6B USD | 23.4B USD |
| Gross profit | 68.56B USD | 61.35B USD | 58.61B USD | 55.39B USD | 55.34B USD |
| Research and development | 14.67B USD | 17.23B USD | 15.09B USD | 14.14B USD | 14.28B USD |
| Selling, general, and administrative | 23.68B USD | 21.97B USD | 20.11B USD | 20.25B USD | 20.12B USD |
| Operating expenses | 42.96B USD | 39.2B USD | 35.2B USD | 34.38B USD | 34.4B USD |
| Interest income | 1.06B USD | 1.33B USD | 1.26B USD | 490M USD | 53M USD |
| Interest expense | 971M USD | 755M USD | 772M USD | 276M USD | 183M USD |
| Depreciation and amortization | 7.5B USD | 7.34B USD | 7.49B USD | 6.97B USD | 7.39B USD |
| Operating income | 25.6B USD | 22.15B USD | 23.41B USD | 21.01B USD | 20.94B USD |
| Net income | 26.8B USD | 14.07B USD | 35.15B USD | 17.94B USD | 20.88B USD |
Company facts updated Sep 6, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$284.79
3.47% upsideCash distributions grouped by calendar year; partial years are marked.
$5.14
2025 complete year+22.7% since 2021
2026 partial: $3.98
$4.19
2,021
$4.45
2,022
$4.70
2,023
$4.91
2,024
$5.14
2,025
$3.98
2,026*
* Partial calendar year in the available dividend history.
| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
Dividend | Aug 25, 2026 | $1.34Quarterly | Aug 25, 2026 | Sep 8, 2026 |
Dividend | May 26, 2026 | $1.34Quarterly | May 26, 2026 | Jun 9, 2026 |
Dividend | Feb 24, 2026 | $1.30Quarterly | Feb 24, 2026 | Mar 10, 2026 |
Dividend | Nov 25, 2025 | $1.30Quarterly | Nov 25, 2025 | Dec 9, 2025 |
Dividend | Aug 26, 2025 | $1.30Quarterly | Aug 26, 2025 | Sep 9, 2025 |
Dividend | May 27, 2025 | $1.30Quarterly | May 27, 2025 | Jun 10, 2025 |
Ex-dividend Aug 25, 2026
$1.34
Quarterly
Record Aug 25, 2026 · Payment Sep 8, 2026
Ex-dividend May 26, 2026
$1.34
Quarterly
Record May 26, 2026 · Payment Jun 9, 2026
Ex-dividend Feb 24, 2026
$1.30
Quarterly
Record Feb 24, 2026 · Payment Mar 10, 2026
Ex-dividend Nov 25, 2025
$1.30
Quarterly
Record Nov 25, 2025 · Payment Dec 9, 2025
Ex-dividend Aug 26, 2025
$1.30
Quarterly
Record Aug 26, 2025 · Payment Sep 9, 2025
Ex-dividend May 27, 2025
$1.30
Quarterly
Record May 27, 2025 · Payment Jun 10, 2025
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI19.65B0.85%2.3T USD0.03%$379.73-0.32%
Vanguard S&P 500 ETFVOO16.2B0.96%1.7T USD0.03%$708.01-0.38%
iShares Core S&P 500 ETFIVV8.68B0.99%878.68B USD0.03%$773.92-0.41%
State Street SPDR S&P 500 ETFSPY8.2B1.00%817.33B USD0.09%$770.19-0.39%
Vanguard Morningstar Value ETFVTV5.88B2.29%256.5B USD0.03%$226.46-0.25%
State Street Health Care Select Sector SPDR ETFXLV4.83B10.72%45.09B USD0.08%$171.45-1.04%
Vanguard Dividend Appreciation ETFVIG3.49B2.66%130.9B USD0.04%$242.02-0.46%
Vanguard High Dividend Yield ETFVYM2.49B2.50%99.2B USD0.04%$164.23-0.40%Vanguard Morningstar Total Stock Market ETFVTIVanguard S&P 500 ETFVOOiShares Core S&P 500 ETFIVVState Street SPDR S&P 500 ETFSPYVanguard Morningstar Value ETFVTVState Street Health Care Select Sector SPDR ETFXLVVanguard Dividend Appreciation ETFVIGVanguard High Dividend Yield ETFVYMAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
